Improving the Diagnosis of Acute Heart Failure Using a Validated Prediction Model  by Steinhart, Brian et al.
H
l
b
w
e
t
C
r
F
a
H
E
e
S
P
C
H
R
P
2
Journal of the American College of Cardiology Vol. 54, No. 16, 2009
© 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00
PHeart Failure
Improving the Diagnosis of Acute Heart
Failure Using a Validated Prediction Model
Brian Steinhart, MD,*§ Kevin E. Thorpe, MMATH,‡** Ahmed M. Bayoumi, MD,*‡††
Gordon Moe, MD,*‡¶ James L. Januzzi, JR, MD,‡‡ C. David Mazer, MD†‡#
Toronto, Ontario, Canada; and Boston, Massachusetts
Objectives We sought to derive and validate a prediction model by using N-terminal pro–B-type natriuretic peptide
(NT-proBNP) and clinical variables to improve the diagnosis of acute heart failure (AHF).
Background The optimal way of using natriuretic peptides to enhance the diagnosis of AHF remains uncertain.
Methods Physician estimates of probability of AHF in 500 patients treated in the emergency department from the multi-
center IMPROVE CHF (Improved Management of Patients With Congestive Heart Failure) trial recruited between
December 2004 and December 2005 were classified into low (0% to 20%), intermediate (21% to 79%), or high
(80% to 100%) probability for AHF and then compared with the blinded adjudicated AHF diagnosis. Likelihood
ratios were calculated and multiple logistic regression incorporated covariates into an AHF prediction model that
was validated internally by the use of bootstrapping and externally by applying the model to another 573 pa-
tients from the separate PRIDE (N-Terminal Pro-BNP Investigation of Dyspnea in the Emergency Department)
study of the use of NT-proBNP in patients with dyspnea.
Results Likelihood ratios for AHF with NT-proBNP were 0.11 (95% confidence interval [CI]: 0.06 to 0.19) for cut-point
values 300 pg/ml; increasing to 3.43 (95% CI: 2.34 to 5.03) for values 2,700 to 8,099 pg/ml, and 12.80
(95% CI: 5.21 to 31.45) for values 8,100 pg/ml. Variables used to predict AHF were age, pre-test probability,
and log NT-proBNP. When applied to the external data by use of its adjudicated final diagnosis as the gold stan-
dard, the model appropriately reclassified 44% of patients by intermediate clinical probability to either low or
high probability of AHF with negligible (2%) inappropriate redirection.
Conclusions A diagnostic prediction model for AHF that incorporates both clinical assessment and NT-proBNP has been de-
rived and validated and has excellent diagnostic accuracy, especially in cases with indeterminate likelihood for
AHF. (J Am Coll Cardiol 2009;54:1515–21) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.05.065a
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meart failure has the second-highest disease burden for
ength of stay in hospitalized patients (1) and is rapidly
ecoming the most expensive disease to manage world-
ide (2,3). Decompensation occurs frequently, and the
mergency department (ED) setting is where most of
hese acute heart failure (AHF) patients present (4).
orrect early diagnosis and treatment is essential to
educe the rate of morbidity and mortality, yet the
rom the Departments of *Medicine and †Anesthesia and Critical Care Medicine,
nd the ‡Keenan Research Center/Li Ka Shing Knowledge Institute, Saint Michael’s
ospital, Toronto, Ontario, Canada; §Department of Medicine, Divisions of
mergency Medicine, General Medicine, and ¶Cardiology, #Departments of An-
sthesia and Physiology, Faculty of Medicine, **Faculty of Medicine, Dalla Lana
chool of Public Health, and the ††Faculty of Medicine, Department of Health
olicy, Management, and Evaluation, University of Toronto, Toronto, Ontario,
anada; and the ‡‡Department of Medicine, Massachusetts General Hospital and
arvard Medical School, Boston, Massachusetts. Dr. Januzzi received grants from
oche Diagnostics, and Siemens. The parent trial, IMPROVE CHF, as well as the
RIDE study were funded by Roche Diagnostics.t
Manuscript received December 10, 2008; revised manuscript received March 30,
009, accepted May 6, 2009.ccurate clinical diagnosis in this setting occurs 80% of
he time (5).
See page 1522
Biomarkers have been used to assist in the diagnosis of
HF for the undifferentiated patient, with B-type natri-
retic peptide (BNP) and N-terminal pro–B-type natri-
retic peptide (NT-proBNP) being the 2 biomarkers most
tudied. When used as dichotomous variables with set
ositive/negative threshold values, the authors of prospec-
ive studies (6,7) have found good sensitivities but relatively
ower positive predictive values for the disease and have
emonstrated a benefit of combining their results with
linical judgment (8). When treated as categorical variables
ith negative, positive, and indeterminate ranges, results show
odest improvement for diagnosing the disease (6–8).
Although national guidelines (9–11) suggest that theseests may be of value in diagnosing AHF when the clinician
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Diagnosis of AHF Using a Model October 13, 2009:1515–21is uncertain, concerns exist as to
the utility of the modest positive
predictive values to rule in AHF,
spectrum bias in the study meth-
odologies, and misapplication of
receiver-operating characteristic
(ROC) test analyses because this
test is not designed for bedside
decision making (12–14). Al-
though it is most likely that anal-
ysis of natriuretic peptide con-
centrations is best performed in a
continuous rather than dichoto-
mous manner, their use in this
way has received very limited at-
tention (15), although evidence
points to a relationship between
a more elevated value and the
presence of heart failure (16).
Describing the relationship be-
ween biomarker values and the probability of AHF could
ield valuable new information (17) that could favorably
ffect critical decision making (18) for this diagnosis, and
he approach of combining clinical variables to such a
ethod of natriuretic peptide interpretation has never been
xamined. Accordingly, we took the approach of analyzing
T-proBNP as a continuous variable by using data from a
reviously reported study (8) of patients presenting to the
D with undifferentiated shortness of breath, deriving and
xternally validating a novel mathematical prediction model
or diagnosing AHF and assessing this approach for appro-
riately redirecting the clinician’s diagnostic impression in
hese cases.
ethods
ata for the present analysis were obtained from a previous
bservational, prospective, blinded cohort study of a conve-
ience sample of 534 patients presenting to 1 of 7 Canadian
rban EDs with undifferentiated shortness of breath. En-
ollment occurred between December 2004 and December
005. Exclusion criteria were either acute myocardial infarc-
ion (defined as any ischemic presentation with either
levation of serum troponin above threshold for acute
oronary syndrome or ST-T changes of 0.1 mV on
lectrocardiogram), renal failure (serum creatinine 250
mol/l; 2.8 mg/dl), malignancy or a case of dyspnea that
learly was without suspicion for AHF (e.g., wheezing in a
6-year-old patient with known asthma).
Consent was obtained, blood tests including NT-
roBNP were drawn, and the patient underwent a history
nd physical examination performed by the emergency
hysician. After the chest radiograph and electrocardiogram
ere reviewed, the emergency physician estimated the
robability of AHF (from 1% to 100%) without knowledge
f the drawn NT-proBNP value. Standard clinical manage-
Abbreviations
and Acronyms
AHF  acute heart failure
BNP  B-type natriuretic
peptide
CI  confidence interval
ED  emergency
department
IDI  integrated
discrimination improvement
LR  likelihood ratio
NRI  net reclassification
improvement
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
ROC  receiver-operator
characteristicent was performed. The NT-proBNP was immunoas- payed by the use of Roche Diagnostics Elecsys proBNP
Indianapolis, Indiana) on Elecsys 1010, 2010, or E170
nstruments. Cross-reactivity and coefficient of variation of
he assays were acceptable.
After completion of the study, adjudication for AHF was
etermined independently by 2 cardiologists by use of the
ramingham Heart Score and NHANES I (National
ealth and Nutrition Examination Survey) Heart Failure
riteria as guides (19,20). Each cardiologist had available all
ndex ED medical charts, further hospital admission test
esults and records (e.g., echocardiogram, computed tomog-
aphy thorax, pulmonary function studies; patient response
o diuretic or broncholytic therapy), and results of a 60-day
ollow-up telephone conversation but were blinded to the
T-proBNP levels. Because AHF is a clinical diagnosis,
heir final diagnoses were considered the “gold standard”
eference for outcome measurements. Full details of the
arent study methodology were described elsewhere (8).
On the basis of the clinician’s assessment, the study
opulation was divided into low pre-test probability
20%), high pre-test probability (80), and intermediate
re-test probability (21% to 79%) subgroups for AHF (15).
e then compared the clinician’s impression to the adju-
icated diagnosis and NT-proBNP value.
The performance characteristics of NT-proBNP as both
categorical and continuous variable were analyzed by
omputing likelihood ratios (LRs) for the diagnosis of AHF
ver a number of NT-proBNP ranges (14). First we
onsidered the current standard ranges in practice of 300
g/ml, 300 and 900 pg/ml, and 900 pg/ml (8). Then
e considered the values as continuous, creating the loga-
ithmic ranges of 300 pg/ml, 300 and 900 pg/ml,
900 and 2,700 pg/ml, 2,700 and 8,100 pg/ml, and
8,100 pg/ml. The LR was calculated as the proportion of
atients with AHF who had a result in the range divided by
he proportion of patients without AHF who had a result in
he range.
We fit a multiple logistic regression model (21) to
etermine whether pre-test probability could be combined
ith NT-proBNP and other covariates to predict AHF.
ecause of the very long right tails in the NT-proBNP
istributions, we used the common logarithm of NT-
roBNP values in the regression model, which “pulled” the
xtreme values closer to the rest of the data. Incorporation
nto a post-test model for AHF was performed by express-
ng the regression model on the probability scale by the
nverse logit transformation. The concordance index or c
tatistic (equivalent to the area under an ROC curve) was
alculated as a measure of discrimination and the bootstrap
ethod was used to validate the model for overfitting (R
anguage 2.5.0, Design Package Version 2.0-12, R Foun-
ation for Statistical Computing, Vienna, Austria).
The calibrated model was examined on an external data
et from the prospective American PRIDE (N-Terminal
ro-BNP Investigation of Dyspnea in the Emergency
epartment) trial of 573 undifferentiated dyspneic EDatients (6). The inclusion/exclusion enrollment criteria and
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October 13, 2009:1515–21 Diagnosis of AHF Using a Modelethodology were similar to our IMPROVE-CHF (Im-
roved Management of Patients With Congestive Heart
ailure) study. These patients were compared with the
MPROVE-CHF cohort by the use of the t test for age and
he Wilcoxon rank sum test for pre-test probability and
T-proBNP variables. All p values were 2-sided, with
alues 0.05 considered significant. The percentage of
RIDE patients appropriately redirected was determined as
as analysis of model improvement.
Our analysis of model improvement used the net reclas-
ification improvement (NRI) and the integrated discrimi-
ation improvement (IDI) as developed by Pencina et al.
22). For a model to improve diagnostic accuracy, patients
ith the condition (AHF) should be reclassified to a greater
isk group whereas those without the outcome (no AHF)
hould be reclassified to a lower risk group. These improve-
ents need to be adjusted for the respective reclassification
rrors (e.g., a patient with the condition is reclassified to a
ower-risk group). This is what the NRI measures but is
ependent on the choice of risk group categories. The
DI is not dependent on risk groups; it can be interpreted
s “the difference between improvement in average sen-
istribution of Caseselative to Pre-Te t ProbabilityTable 1 Distribution of CasesRelative to Pre-Test Probability
Pre-Test Probability of AHF
(Group)
Adjudication Diagnosis
AHF No AHF Total
20% 26 (16.0) 137 (84.0) 163 (33.7)
21%–79% 80 (43.5) 104 (56.5) 184 (38.1)
80% 115 (84.6) 21 (15.4) 136 (28.2)
Total 221 (45.8) 262 (54.2) 483 (100)
alues are n (%).
AHF  acute heart failure.
Figure 1 Comparison of NT-proBNP Levels With Physician Estim
AHF  acute heart failulre; NT-proBNP  N-terminal pro–B-type natriuretic peptide.itivity and any potential increase in average ‘one minus
pecificity’” (22).
esults
ive hundred thirty-four patients were enrolled, and 34
atients were excluded because of protocol violation or not
ulfilling inclusion/exclusion criteria. Of the 500 patients
emaining, 17 data forms for pre-test probability were
ncomplete, resulting in 483 patient data analyzed. The
verage age was 70 years, with no significant difference in
ex; further baseline characteristics and demographics are
ully described elsewhere (8).
Adjudication for AHF resulted in discordance for diag-
osis in 10 cases of 483; all 10 cases were ultimately agreed
pon. The prevalence of adjudicated AHF in the 3 pre-test
robability groups is shown in Table 1. The largest group
as the intermediate clinical probability group with 38% of
otal patients (184 of 483) and an adjudicated AHF prev-
lence of 43%. The overall study prevalence for adjudicated
HF was 46%.
Distribution of NT-proBNP values within each pre-test
roup (Fig. 1) showed a trend toward lower values in the
djudicated no AHF subgroup compared with the AHF one
ut with significant overlap between the 2; this relationship
ontinued between all 3 pre-test groups. Overall median
T-proBNP values for “no AHF” and “AHF” patients were
20 and 3,820 pg/ml, respectively. The values were skewed
ith overlap between the 2 groups. Use of the logarithm of
he value, as expected, brought considerably more symmetry
o the distribution.
Table 2 and Figure 2 depict the LRs and post-test
robabilities by the use of standard threshold cut points and
ultiple cut points for ruling in/out AHF. The LR for the
of Pre-Test Probability of AHFate
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Diagnosis of AHF Using a Model October 13, 2009:1515–21owest NT-proBNP range of 300 pg/ml had a value of
.11 with narrow confidence intervals (CIs). The LRs for
he other 2 ranges of 300 to 899 pg/ml and 900 pg/ml
ere 0.34 (95% CI: 0.19 to 0.60) and 2.75 (95% CI: 2.29 to
.30), respectively. Analyzing NT-proBNP values by ex-
anding the number of intervals 900 pg/ml from 1 to 3
llowed much more information to become available—the
Rs for AHF with NT-proBNP ranged from 0.11 (95%
I: 0.06 to 0.19) for values 300 pg/ml to 12.80 pg/ml
LRs for Standard and Multiple NT-proBNP Cut PTable 2 LRs for Standard and Multiple NT-pr
NT-proBNP Cut Point (pg/ml) AHF
LRs for standard NT-proBNP cut points
300 12
300899 14
900 195
LRs for multiple NT-proBNP cut points
300 12
300899 14
9002,699 57
2,7008,099 84
8,100 54
LR  likelihood ratio; NT-proBNP  N-terminal pro–B-type natriuretic
Figure 2
Utility of Multiple NT-proBNP Cut Point Values
for Altering Pre-Test Probability for AHF
Based on Likelihood Ratios
Points further from the hypothetical null diagonal enhance change in pre-test
probability. Points below it are in the rule-out AHF zone, points above it are in
the rule-in zone, and points further from the diagonal in either direction
enhance change in pre-test probability. Thus, the interval of 300 pg/ml has
good rule-out AHF utility, and much less so the 300 to 899 pg/ml interval.
Increasing the number of intervals for the greater NT-proBNP values adds incre-
mental rule in AHF utility. Patients with pre-test probabilities 20% or 80%
demonstrate minimal change in post-test results regardless of range of cut
point. Patients with pre-test probabilities between 20% and 80% demonstrate
the greatest change in post-test results. Abbreviations as in Figure 1.t95% CI: 5.21 to 31.45) for values 8,100 pg/ml; for
ntermediary ranges of 300 to 899 pg/ml, 900 to 2,699
g/ml, and 2,700 to 8,099 pg/ml LR values remained
odest. Only the 8,100 range had an acceptable LR
12.80) for diagnosing AHF (23).
When patient age, pre-test probability of AHF, and
og(NT-proBNP) were used, the logistic regression fit
ielded a model for estimating the probability that a patient
ad AHF (Online Appendix). This model had a concor-
ance index of 0.905, which indicated excellent discrimina-
ion. Bootstrap validation indicated negligible overfitting,
nd the model was well calibrated internally. External
alidation on 573 cases confirmed excellent discrimination
c  0.97) but did show some unreliability. Specifically the
odel tended to underestimate the true probability of AHF
n the external data despite applying linear logistic calibra-
ion for prediction. We have used the uncalibrated model
or simplicity.
Of 600 patients previously reported in the PRIDE study
rom Boston, 573 had complete data analyzed for this
tudy. When compared with the IMPROVE-CHF study,
ge, pre-test probability, and NT-proBNP values were all
ound to be significantly different (Table 3) (p  0.001).
ost of the reclassification improvement occurred in the
ntermediate-probability category, as shown in Table 4.
hen applied to the pre-test low-probability risk group of
43 patients where the clinician was quite sure the diagnosis
as not AHF, the model confirmed what the clinician
lready suspected in 276 of 282 patients but inappropriately
edirected several patients to the intermediate probability
ategory (30 of 58 patients), with few appropriately to high
robability (3 of 3 patients). When the model was applied to
he pre-test high-probability risk group of 91 patients where
he clinician was quite sure the diagnosis was AHF, the
ame trend occurred. With most pre-test high-probability
atients, the model verified what the clinician already
hought (72 of 73 patients) but inappropriately redirected
ost of the remaining patients to the intermediate-
robability category (14 of 18 patients).
When applied to the pre-test intermediate probability
isk group where the clinician was most in need of diagnos-
Cut Points
AHF LR 95% Confidence Interval
129 0.11 0.060.19
49 0.34 0.190.60
84 2.75 2.293.30
129 0.11 0.060.19
49 0.34 0.190.060
50 1.35 0.971.89
29 3.43 2.345.03
5 12.80 5.2131.45
; other abbreviations as in Table 1.ointsoBNP
Noic help, the model redirected the clinician to either low or
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October 13, 2009:1515–21 Diagnosis of AHF Using a Modeligh probability with an extremely high rate of appropri-
teness; in fact 44% (95% CI: 40% to 49%) of the initial
re-test intermediate probability patients (37  24 of 139)
ould be appropriately reclassified to either the low or high
robability risk group and only 1 patient inappropriately
eclassified. The model was an improvement to clinical
udgment alone as measured by NRI and IDI (22). The
RI was 0.23 (p 0.001), and the IDI was 0.11 (p 0.001),
hich are both considered large degrees of improvement.
iscussion
e have derived and externally validated a new mathemat-
cal model for improving the diagnosis of AHF in patients
ith undifferentiated dyspnea. Although more complex
han the use of NT-proBNP as a dichotomous variable, the
se of the marker as a continuous variable provided further
nhancement of the diagnosis for AHF than when used as
categorical test. The use of a mathematical model for
iagnostic medicine is innovative, as is its analysis by NRI
nd IDI for appropriately redirecting the clinician.
The authors of previous biomarker studies (6,8,15,24)
ave emphasized sensitivity, specificity, and ROC curve
nalyses that are test performance measures but were not
ecessarily designed to be used for decision making on
omparison of Study Patient PopulationsTable 3 Comparison of Study Patient Populations
Study Population IMPROVE-CHF PRIDE p Value
Age, yrs (SD) 70.2 (14.3) 62.5 (17.1) 0.001
Pre-test probability 0.001
Minimum 0 0
First quartile 0.10 0
Median 0.40 0.10
Third quartile 0.80 0.50
Maximum 0.999 0.999
NT-proBNP (pg/ml) 0.001
Minimum 5 5
First quartile 206 81.5
Median 1,299 461.4
Third quartile 4,219.5 2,643.5
Maximum 35,585 117,390
MPROVE-CHF  Improved Management of Patients With Congestive Heart Failure; PRIDE 
-Terminal Pro-BNP Investigation of Dyspnea in the Emergency Department; other abbreviations
s in Table 2.
odel Versus Clinical Impression for Diagnosing Acute HF Based oTable 4 Model Versus Clinical Impression for Diagnosing Acute
Pre-Test Risk Group Post-Test Risk Group Adjudi
LP, n  343 (accuracy  89%) LP (n 282)
IP (n 58)
HP (n 3)
IP, n  139 LP (n 38)
IP (n 77)
HP (n 24)
HP, n  91 (accuracy  95%) LP (n 0)
IP (n 18)
HP (n 73)Inappropriately not reclassified (i.e., falsely not redirected).
HF  heart failure; HP  high probability; IP  intermediate probability; LP  low probability.ndividual patients (14). Positive and negative predictive
alues may enable clinicians to interpret biomarker values in
more meaningful way but they are influenced by the
revalence rates, which vary between studies (14). To
inimize prevalence effect and facilitate decision making at
he bedside, a more appropriate analysis is to calculate
ikelihood ratios (23,25,26). A recent systematic review of
he English language literature found a pooled positive LR
f 3.3 for BNP or NT-proBNP for diagnosing AHF (27).
Our resultant findings support a strategy for treating
atriuretic peptide values as continuous, which obviates the
eed for clinicians to remember cut points or stratify them
y age, which further strengthens the notion that although
ut points are necessary to define boundaries of disease
tates, interpretation of biomarkers such as BNP or NT-
roBNP as continuous variables (in conjunction with com-
ining clinical variables and expert judgment) is a superior
pproach (28).
The patients in whom the clinicians are indecisive for the
iagnosis may very well be the best target for natriuretic
eptide testing because these patients are those in whom
orse clinical outcomes have been observed (29). Indeed it
s with these “gray zone” cases that clinicians most often
eed ancillary tests, and our data lend further support of this
bservation in that the pre-test LR for AHF in our
ntermediate group was 0.9, which approximates the LR of
, suggesting clinical impression alone in this cohort holds
ittle significance for the final diagnosis (14). Application of
ur model to the intermediate pre-test study group redi-
ected close to one-half of patients, with a 99% accuracy.
eferencing the McCullough et al. (15) landmark study
nalysis demonstrating 74% appropriate diagnosis using cut
oints in this patient cohort, it would appear use of the
odel would correctly diagnose one-quarter fewer of these
atients but would also avoid inadvertently misdiagnosing
he same amount. Clinical discretion would dictate the
referred approach to be used.
Incorporating a diagnostic test value into clinical assess-
ent to create a diagnostic prediction rule for the presence
r absence of a disease has shown to be of clinical benefit in
ther disease states (30); however, few studies on AHF have
sed this type of analysis. Baggish et al. (16) analyzed a
ernal Pre-Test Risk Groupased on External Pre-Test Risk Group
No HF Adjudicated HF Percent Appropriately Reclassified
6 (2.1)*
28 48.3
3 100
1 97.3
52 —
24 100
0 0
14 22.2
72 (1.4)*n ExtHF B
cated
276
30
0
37
25
0
0
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Diagnosis of AHF Using a Model October 13, 2009:1515–21tudy of 599 dyspneic patients to create an effective scoring
ool for diagnosing AHF that required the integration of 7
linical factors with the dichotomous NT-proBNP value
nd have recently published the derivation of this and a
yspnea risk score into an electronic format for personal
igital assistant-type devices (31). These data and ours both
upport the concept that NT-proBNP values should be
ombined with clinical variables into a prediction calcula-
ion to be most useful to clinicians.
We believe our study makes intuitive sense to those
linicians who have experience in the use of BNP or
T-proBNP. Although discrete cut points allow for ease of
se, they are often derived from clinical trials that may not
ave a typical cross section of those patients who are tested
n “real life” situations, which leads to LRs that are less
tatistically robust, and aggregate clinical experience with
atriuretic peptides would indicate that in fact many diag-
oses, including acute coronary syndrome or pulmonary
mbolism, may result in elevations of these markers into the
ange that is consistent with AHF. Accordingly clinicians
ften approach markers such as BNP and NT-proBNP as
ontinuous variables, recognizing that greater values are
ore consistent with AHF (28); this approach has been
ecommended as superior by recent consensus guidelines
32) but until now had not been analyzed in a rigorous
ashion. By analyzing NT-proBNP as a continuous variable,
e found that the model supplants this unstudied approach.
The incorporation of clinical impression as part of a
rediction model in this study reaffirms most clinicians’
elief that their impressions should directly contribute
oward any prediction rule (33,34). The model also does not
equire elaborate clinical information and is therefore rela-
ively simple to use. Thus, for many undifferentiated dys-
neic cases the model appears to quickly and reliably
edirect the undecided clinician for diagnosing AHF. It
ould ultimately lead to improved health outcomes and
treamlined research in this very challenging patient
opulation.
A recent study (29) has shown that clinicians may be
naccurate for ruling in or ruling out AHF despite high
evels of certainty and that the addition of biomarker testing
n this setting may improve judgment. The application of
ur model on the external database showed excellent appro-
riate reclassification in the intermediate-probability clinical
roups. In the other risk groups the model showed modest
ppropriate reclassification; it should be emphasized that in
ituations of reclassification, clinical judgment is necessary
o correctly interpret the results. Future studies in various
ettings will clarify the model utility across all levels of
linical certainty.
tudy limitations. The model uses the clinician assessment
f pre-test probability, which makes it potentially vulnerable
o interobserver variability for any given case. There may be
ifferences across institutions as well, such as between
cademic and nonacademic settings or those with differing
HF rates. A study (35) of another disease shows greatergreement rates than expected, and standardized explicit
1ata forms (36) have demonstrated more inter-rater dis-
greement than anticipated. As well, with our approach
here is less reason for “clinician override” of the model as
an occur with other rules, because clinical impression is
eighted heavily in the model calculation. Future studies are
eeded to prospectively analyze inter-rater error for AHF
re-test probability (37). It is possible that more objective
ariables could replace the clinical estimate. Although AHF
an accompany acute coronary syndromes, caution should
e exercised when extrapolating results to patients with
bnormal troponin values because these patients were out-
ide of the spectrum of patients studied. We omitted age
tratification in our analysis of standard NT-proBNP cut
oints as the numbers of study patients 50 years and 75
ears of age were too few to draw meaningful conclusions;
owever, age as a significant variable for AHF was incor-
orated into the model. Another issue relates to the external
alidation of the model, which while confirming excellent
odel discrimination (c  0.97), did show some unreliabil-
ty in that the model tended to underestimate the true
robability of AHF. As such, the model’s rate of appropri-
te redirection calculated on the external data is likely
onservative.
Although we did not analyze BNP in this study, BNP
uffers from the same issues regarding cut points as NT-
roBNP (38). Although currently not generalizable to all
ettings, the fact that the 2 study cohorts were from different
ountries and so different (Table 3) suggests the model may
erform well in other patient populations. Finally, the
omplex mathematics of the model formula can be seen as
deterrent for its use; methods for optimal implementation
eed to be studied including websites, PDA devices and
ospital laboratory reporting systems.
onclusions
diagnostic prediction model for AHF that uses clinical
ssessment and NT-proBNP value has been derived and
xternally validated to appropriately direct the physician in a
ignificant number of indeterminate cases. Further studies
f implementation, cost, and impact analyses will help
efine the model’s general utility across all levels of clinical
ertainty and may foster similar analyses of other categorical
iagnostic tests.
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APPENDIXor the prediction model, please see the online version of this article.
